Finally, further evidence to support miR-494 as a potential future therapeutic agent came from a study that investigated mechanisms leading to resistance towards osimertinib in SCLC; here, the authors found that an elevated expression of this miR was associated with resistance to this EGFR inhibitor. The gene discussed is EGFR; the disease is small cell lung carcinoma.